Crizotinib (PF-02341066)

For research use only. Not for use in humans.

Pfizer辉瑞授权 目录号:S1068

Crizotinib (PF-02341066) Chemical Structure

CAS No. 877399-52-5

Crizotinib (PF-02341066) 克唑替尼是一种有效的c-MetALK抑制剂,在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂,其Ki值小于0.025 nM。Crizotinib可在多种肺癌细胞系中通过抑制STAT3通路来诱导自噬。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1812.55 现货
RMB 900.49 现货
RMB 1372.81 现货
RMB 4681.47 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Crizotinib (PF-02341066)发表文献285篇:

产品安全说明书

c-Met抑制剂选择性比较

生物活性

产品描述 Crizotinib (PF-02341066) 克唑替尼是一种有效的c-MetALK抑制剂,在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂,其Ki值小于0.025 nM。Crizotinib可在多种肺癌细胞系中通过抑制STAT3通路来诱导自噬。
靶点
ROS1 [6]
(Cell-free assay)
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
<0.025 nM(Ki) 11 nM 24 nM
体外研究

PF-2341066作用于mIMCD3小鼠和MDCK犬上皮细胞,作用于c-Met磷酸化作用时具有相似效果,IC50分别为5 nM 和20 nM。PF-2341066作用于表达c-Met ATP-结合位点突变型V1092I 或H1094R或 P-环突变 M1250T 的NIH3T3 细胞,具有相似的活性,且活力增高,IC50分别为19 nM,2 nM 和15 nM,而作用于表达野生型受体的NIH3T3 细胞时,IC50为13 nM。[1] 相反, 观察到PF-2341066作用于表达c-Met活化环突变型Y1230C 和Y1235D的细胞时,与作用于野生型受体相比,效果发生显著改变,IC50分别为127 nM 和92 nM。PF-2341066 作用于分别表达内源性c-Met 突变体R988C和 T1010I 的NCI-H69 和HOP92 细胞,也有效抑制c-Met 磷酸化, IC50分别为13 nM 和16 nM。与作用于c-Met相比,PF-2341066作用于VEGFR2 和PDGFRβ RTKs, 选择性高1000多倍,作用于IRK和Lck选择性高250多倍,作用于Tie2, TrkA,和TrkB选择性高40到60倍。PF-2341066 作用于RON和 Axl RTKs时选择性为20到30倍。相反,PF-2341066 作用于表达ALK RTK 的核磷蛋白 (NPM)- 间变性淋巴瘤激酶(ALK) 致癌融合突变体和 KARPAS299人间变性大细胞淋巴瘤(ALCL)细胞系时具有相近的IC50值,为24 nM。PF-2341066抑制c-Met依赖的癌细胞的肿瘤表现型,和内皮细胞的血管生成表现型。PF-2341066抑制人GTL-16胃癌细胞生长,IC50为9.7 nM。PF-2341066诱导 GTL-16细胞凋亡,IC50 为8.4 nM。PF-2341066 抑制HGF刺激的人NCI-H441肺癌细胞迁移和入侵,IC50分别为11 nM 和6.1 nM。PF-2341066抑制 MDCK细胞散射,IC50为16 nM。PF-2341066 抑制HGF-刺激的c-Met磷酸化,细胞存活,和Matrigel入侵,IC50分别为11 nM, 14 nM和35 nM。此外, PF-2341066抑制纤维蛋白胶中的血清刺激的 HMVEC分支小管形成 (形成血管)。[1] PF-2341066 作用于Karpas299 或SU-DHL-1 ALCL细胞,也有效抑制 NPM-ALK磷酸化,IC50 为24 nM。PF-2341066 有效抑制细胞增殖,伴随着使细胞周期停在G(1)-S期,且诱导 ALK阳性的 ALCL 细胞凋亡,IC50为30 nM, 但是作用于ALK阴性的淋巴瘤细胞则无效果。 [2] 此外, PF-2341066 抑制骨肉瘤的一些活动行为,及其肿瘤生长 (例如,增殖和存活)和转移 (例如,入侵和形成克隆)。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 NUHrc|dHS3m2b4TvfIlkKEG|c3H5 Mkj1OFghcA>? MnjJSG1UVw>? MoXhR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCwMlYzKM7:TR?= NFrEOVUzOTV5MkW4PS=>
BAF3 M3zuS2N6fG:2b4jpZ{BCe3OjeR?= NGjK[YY1QCCq MoPqSG1UVw>? NXLDflFxS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIFHMT{BNOTF7Nl2gcZV1[W62IHPv[ZhxemW|c3nu[{BGVUx2IIfpeIghUUN3MDDv[kAzNjJizszN NIDv[2MzOTV5MkW4PS=>
BAF3 MoHDR5l1d3SxeHnjJGF{e2G7 NWfabJVWPDhiaB?= NGfndlBFVVOR MlXUR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKHerdHigTWM2OCCxZjCwMlI5KM7:TR?= MkS2NlE2PzJ3OEm=
Kelly NYfVbG5DS3m2b4TvfIlkKEG|c3H5 MmDXSG1UVw>? NVjsVVdwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU2WubImgZ4VtdHNiZYjwdoV{e2mwZzDBUGshTjFzN{TMJI12fGGwdDD3bZRpKEmFNUCgc4YhOC52MjFOwG0> MYSyNVU4OjV6OR?=
SH-SY5Y MnTSR5l1d3SxeHnjJGF{e2G7 NHPE[|NFVVOR MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPTNizszN MkTVNlE2PzJ3OEm=
SMS-KCN M2jJXWN6fG:2b4jpZ{BCe3OjeR?= NUDK[214TE2VTx?= NGTJdZZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUVVNvS1POJINmdGy|IHX4dJJme3OrbnegRWxMKFJzMke1VUBufXSjboSge4l1cCCLQ{WwJI9nKDBwOUGg{txO MX[yNVU4OjV6OR?=
BAF3 MXXDfZRwfG:6aXOgRZN{[Xl? M3jsO|Q5KGh? M3TwZmROW09? NHPnSHJEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiVHXsMWFNUyC5aYToJGlEPTBib3[gNE4yQSEQvF2= NGix[WMzOTV5MkW4PS=>
3T3 NWn1dJgyTnWwY4Tpc44hSXO|YYm= NUXt[JFuOSCq NV6x[nR5TE2VTx?= NHH0elFKdmirYnn0bY9vKG:oIGLPUkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1? MmLyNlE5OTJ2MUS=
3T3-E NYXsOHk5TnWwY4Tpc44hSXO|YYm= MXyxJIg> M{X4e2ROW09? NYXzN3NEUW6qaXLpeIlwdiCxZjDUTWUzKGG|c3Xzd4VlKGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkS0PEDPxE1? NHvjOIwzOThzMkSxOC=>
A549 MoP5T4lv[XOnIFHzd4F6 NWPmRm1FOSCq NYfqSmVoTE2VTx?= NHjReVNKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IHOtUWVVKGurbnHz[UBmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBJT0ZvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByODFOwG0> MUGyNVgyOjRzNB?=
BAF3-BCL NUnadpN4TnWwY4Tpc44hSXO|YYm= NEDxW2oyKGh? M33JfGROW09? MUjJcohq[mm2aX;uJI9nKEGETDDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOS5zNUmg{txO MX:yNVgyOjRzNB?=
HEK293 M4fI[GZ2dmO2aX;uJGF{e2G7 M{HNXVEhcA>? NED1TFRFVVOR M2\ZVGlvcGmkaYTpc44hd2ZiQWjMJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkK5OEDPxE1? M1n3dFIyQDF{NEG0
HEK293 M4i4Z2Z2dmO2aX;uJGF{e2G7 NXLhSYdoOSCq MkHTSG1UVw>? MnTrTY5pcWKrdHnvckBw\iCLUjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi56OEeg{txO MmjRNlE5OTJ2MUS=
Jurkat NVLiVoFMTnWwY4Tpc44hSXO|YYm= NV22NFI{OSCq MVvEUXNQ M2jJVWlvcGmkaYTpc44hd2ZiTFPLJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iB{Lke0NUDPxE1? MVSyNVgyOjRzNB?=
KARPAS299 NHznXINMcW6jc3WgRZN{[Xl? NUPZSGZKOSCq NV3qU21STE2VTx?= MYXJcohq[mm2aX;uJI9nKEGOSzDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMjFOwG0> NHO2UpAzOThzMkSxOC=>
PAE NELOfZFHfW6ldHnvckBCe3OjeR?= NELEeoYyKGh? Moj1SG1UVw>? MmrUTY5pcWKrdHnvckBw\iCWUlvCJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkO5PUDPxE1? MofqNlE5OTJ2MUS=
BAF3 NIHMWWdHfW6ldHnvckBCe3OjeR?= M3juZ|IuOyCm NVywZ|NqTE2VTx?= MlH6TY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiaX7zeYxqdiC{ZXPldJRweiCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEvPjR|IN88US=> M4PmTVI{PzR{MkWy
KARPAS299 MVTDfZRwfG:6aXOgRZN{[Xl? NIHXcoMzNTNiZB?= NWq4bnAxTE2VTx?= M4ns[2lEPTB;MD6wOlQzKM7:TR?= NIqyUWQzOzd2MkK1Ni=>
EBC1 NFGz[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrIXYQ3PzJiaB?= M3XoUmROW09? NYTaPVE2UUN3ME2wMlAzOyEQvF2= MUWyN|k6OzN{OB?=
HCT116 NEPDem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknWO|IhcA>? NYTRWo0{TE2VTx?= MnTMTWM2OD1zND64NkDPxE1? NWHwTJo2OjN7OUOzNlg>
MCF7 NGXwe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\ZcZAxPzJiaB?= M2jxcGROW09? NHOwXWtKSzVyPUmuOVgh|ryP M1;qPFI{QTl|M{K4
MDA-MB-231 MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zv[|czKGh? NF;KOllFVVOR NIHWcWZKSzVyPUGwMlgh|ryP NFnwO2EzOzl7M{OyPC=>
MKN45 M4faZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUW3NkBp MmLJSG1UVw>? M1racGlEPTB;MD6wNVMh|ryP NHj1eHIzOzl7M{OyPC=>
NCI-H441 M{\QNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XjT|czKGh? NVSyTW1ZTE2VTx?= NHe3VYRKSzVyPUG3MlI2KM7:TR?= NYPvOpA2OjN7OUOzNlg>
NCI-H661 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnvWItJPzJiaB?= MoDkSG1UVw>? MVvJR|UxRTFzLkS3JO69VQ>? NX3RVnJxOjN7OUOzNlg>
SK-MEL-28 MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fRZ|czKGh? M3j1UWROW09? NF7zT21KSzVyPUGwMlk4KM7:TR?= MWCyN|k6OzN{OB?=
SKOV3 NWDnNpBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXD[Gg4OiCq M4Xo[2ROW09? MkL1TWM2OD1zMj64OUDPxE1? M3rLclI{QTl|M{K4
SNU5 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\6NFA4OiCq MmO0SG1UVw>? M2O3W2lEPTB;MD6wNVYh|ryP NVPJUlMzOjN7OUOzNlg>
NCI-H2228 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\HT2x3PzJiaB?= M2DjdmROW09? NXv3WGFPUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUG4JO69VQ>? MnP6NlQ1OzJ7MEm=
NCI-H3122 MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Xnc|czKGh? NXfQVlJtTE2VTx?= M37tSGlvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjFyODFOwG0> M3TXPVI1PDN{OUC5
NCI-H3122 NHTydWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvHO|IhcA>? NHrk[plFVVOR M3\vS2lvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIHnuJIh2dWGwIF7DTU1JOzF{MjDj[YxteyCqYYLic5JqdmdiQVzLJGcyOjZ7QTDteZRidnRid3n0bEBKSzVyIH;mJFAvPjJ|IN88US=> NXvJTZNWOjR2M{K5NFk>
NCI-H3122 NHvj[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUW3NkBp NHXOT5pFVVOR NHTCUIJKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiaHHyZo9zcW6pIFHMT{BNOTF7Nl2gcZV1[W62IIfpeIghUUN3MDDv[kAxNjh|ODFOwG0> NXq1[FdNOjR2M{K5NFk>
NIH-3T3 MoTmT4lv[XOnIFHzd4F6 M2L6d|EhcA>? MWjEUXNQ NF7BNlZKdmirYnn0bY9vKG:oIHj1cYFvKHerbHSgeJlx\SCHTVy0MYZ2e2WmIFHMT{BmgHC{ZYPz[YQh[XO|ZYPz[YQh[XNicHjvd5Bpd3K7bHH0[YQhSUyNIHzleoVtKHerdHigTWM2OCCxZjCwMlA5KM7:TR?= Mme3NlQ1OzJ7MEm=
NIH-3T3 MYHLbY5ie2ViQYPzZZk> M3;WSlEhcA>? NH30bIJFVVOR MkjjTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDHNVI3QUFibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC54MEWg{txO NYnxVZR3OjR2M{K5NFk>
NIH-3T3 NF3iNmJMcW6jc3WgRZN{[Xl? MWmxJIg> NV7uPGRHTE2VTx?= NV7NPYRYUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BUOTJyNmmgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NlYh|ryP M2TlTFI1PDN{OUC5
NIH-3T3 M4nIZmtqdmG|ZTDBd5NigQ>? MoPvNUBp MYTEUXNQ NXfXV4t1UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BNOTF7Nl2gcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD64OFMh|ryP NYDK[3FyOjR2M{K5NFk>
NIH-3T3 NU\XfHV1U2mwYYPlJGF{e2G7 NVSyXmFyOSCq MnLNSG1UVw>? MVPJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVUzWiCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAyNjB{NjFOwG0> MoHkNlQ1OzJ7MEm=
BAF3 M4HSTGZ2dmO2aX;uJGF{e2G7 NULGS|dbPzJiaB?= M{HDfmROW09? Mmm1TY5pcWKrdHnvckBw\iCQUF2vRWxMKHS{YX7z[oVkfGWmIHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODVzIN88US=> NIXmN2QzPDR4OE[zNi=>
BAF3 Mki0R5l1d3SxeHnjJGF{e2G7 M2XT[VczKGh? NVT2R2lDTE2VTx?= MYnJR|UxRTBwOUig{txO MmDYNlQ1Pjh4M{K=
NIH-3T3 NHjw[lNMcW6jc3WgRZN{[Xl? M17iNlEhcA>? M3n4dGlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugSlEyPzSOIH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwMU[1JO69VQ>? MYSyOFgyQTFzNh?=
NIH-3T3 NU\jPW41U2mwYYPlJGF{e2G7 MlTRNUBp MXvJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFOxNVU3YSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjR5ODFOwG0> NYfSWJBYOjR6MUmxNVY>
NIH-3T3 NV3pO3RDU2mwYYPlJGF{e2G7 M1[5TFEhcA>? MnTlTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDHNVIxOlJibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOS5zNEig{txO M3ryTlI1QDF7MUG2
NIH-3T3 NI\yco5McW6jc3WgRZN{[Xl? NXXNUms3OSCq MXnJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIEGxOVFVcW6|IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDNwMEO5JO69VQ>? MnzMNlQ5OTlzMU[=
KARPAS299 NVnyfGkyU2mwYYPlJGF{e2G7 NFP3NZE6OCCvaX6= NFjCe3pFVVOR MXfJcohq[mm2aX;uJI9nKE6STT3meZNm\CCDTFugdIhwe3Cqb4L5cIF1cW:wIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5zMTFOwG0> NGHLVYUzPDlyMEe1NC=>
MKN 45 MYTLbY5ie2ViQYPzZZk> MV[xJIg> NHjydYNFVVOR MkX1TY5pcWKrdHnvckBw\iClLV3leEBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKg{txO NX72NWJYOjR7MEC3OVA>
A549 NYfEfG5tS3m2b4TvfIlkKEG|c3H5 MoGyOFghcA>? Mn3VSG1UVw>? MWLJR|UxKG:oIESuNFg1KM7:TR?= NFyxSmUzPDlyMEizNC=>
NCI-H1975 NX3kT3p4S3m2b4TvfIlkKEG|c3H5 Mk\4OFghcA>? MlTsSG1UVw>? MUfJR|UxKG:oIEeuOVUyKM7:TR?= Mn\4NlQ6ODB6M{C=
NCI-H1993 NXTTRlJFS3m2b4TvfIlkKEG|c3H5 Mor5OFghcA>? M3XFdmROW09? MXTJR|UxKG:oIECuNFYyKM7:TR?= M1TZdVI1QTByOEOw
NCI-H1993 M1W4b2Fxd3Sxc3nzJGF{e2G7 NHW1e2YyKM7:TR?= M3LjdFI1KGh? M1:xb2ROW09? MUDkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m| NH;TWIUzPDlyMEizNC=>
NIH-3T3 MXzDfZRwfG:6aXOgRZN{[Xl? M1rDfVQ5KGh? MWjEUXNQ MmDrTWM2OCCxZjCwMlM3PCEQvF2= NInVOXAzPDlyMEizNC=>
EBC1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jsb|czKGh? NXy2TGh{TE2VTx?= NETCW2FKSzVyIH;mJFAvODB4OTFOwG0> NHvQS3AzPDlyMEizNS=>
KARPAS299 M1fFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWq3NkBp Mm\iSG1UVw>? MWLJR|UxKG:oIECuNkDPxE1? M17tR|I1QTByOEOx
NB1 MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PkUGlEPTB;OUGuPVghdk1? NY\6fVE{W0GQR1XS
NCI-SNU-5 M4O3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DxSWlEPTB;MUC1Mlc2KG6P MnK4V2FPT0WU
SR M{DGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXW2bpFUUUN3ME2xNlYvOzFibl2= NInXOGdUSU6JRWK=
SF539 M3rZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrLTWM2OD1{MESuNlQhdk1? MVXTRW5ITVJ?
SU-DHL-1 NEPVRVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTN|Nj64NkBvVQ>? NV;x[lhlW0GQR1XS
SCC-3 MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HI[2lEPTB;M{W2Mlc3KG6P NFnjdmZUSU6JRWK=
DEL M4Hvcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Hk[2lEPTB;M{[5Mlkhdk1? NG\tVmpUSU6JRWK=
CTV-1 M2nFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3BTWM2OD13OU[uOFghdk1? MYrTRW5ITVJ?
EM-2 MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17vbWlEPTB;NkCxMlM1KG6P M2XONXNCVkeHUh?=
MHH-CALL-2 MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;xeI5KSzVyPU[4Nk42PyCwTR?= MWLTRW5ITVJ?
KM12 MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLnbHBNUUN3ME23NFYvQSCwTR?= M4fIZnNCVkeHUh?=
KINGS-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;tOXNxUUN3ME23OFkvPzVibl2= NILRenBUSU6JRWK=
MEG-01 NIjmcnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PjZWlEPTB;OEW3MlY3KG6P M3u3OHNCVkeHUh?=
BV-173 NXvUTZZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PzfGlEPTB;MT6wOVk6PyEQvF2= MnL4V2FPT0WU
LAMA-84 NGrvUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[0TWM2OD1zLkO4NlgzKM7:TR?= NELwTnNUSU6JRWK=
KARPAS-299 NH3PbHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G4bmlEPTB;MT60NFg3OSEQvF2= M1PyO3NCVkeHUh?=
K-562 NUPzcI9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX5cJR1UUN3ME2xMlczOjZ7IN88US=> MX3TRW5ITVJ?
SK-LMS-1 Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHKd5pxUUN3ME2xMlc3QDZ5IN88US=> M2LrTHNCVkeHUh?=
MOLT-16 NFXY[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq4TWM2OD1zLkm1OVc2KM7:TR?= NUDEZo15W0GQR1XS
CMK NUfTbok2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XCfWlEPTB;MT65OlE2QSEQvF2= MXXTRW5ITVJ?
ST486 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\CTmlEPTB;Mj60N|A4OyEQvF2= M3rOWHNCVkeHUh?=
CI-1 NVXFOVlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfnTWM2OD1{LkS5OlU6KM7:TR?= MmK4V2FPT0WU
KP-N-RT-BM-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;YTWM2OD1{LkewNVIzKM7:TR?= NFXFflZUSU6JRWK=
ALL-PO NInt[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLmTWM2OD1|LkG4NlA4KM7:TR?= MV;TRW5ITVJ?
KS-1 MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTNwMkGyNlUh|ryP NXvO[|l1W0GQR1XS
Becker MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3nTWM2OD12LkKzPVMh|ryP NIXpOVdUSU6JRWK=
GDM-1 MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjQbZJDUUN3ME20MlI1PjF5IN88US=> NGLxbGhUSU6JRWK=
BC-1 NXHFRmZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjyTWM2OD12LkS5Nlc4KM7:TR?= M2DsV3NCVkeHUh?=
NB14 MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG2R41KSzVyPUSuPFM2OjRizszN Mlf5V2FPT0WU
NOS-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDpfGhKSzVyPUWuN|M5PzRizszN M2\CUHNCVkeHUh?=
MZ1-PC NGXmUZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W0c2lEPTB;NT64NlE2OSEQvF2= NXPzSZQ{W0GQR1XS
A498 NUjO[Vh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LlRmlEPTB;Nj6wPFQ4OyEQvF2= MkW2V2FPT0WU
EW-16 M1y3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvFTWM2OD14LkO3O|c{KM7:TR?= NV\DUnFiW0GQR1XS
NALM-6 NVfCeoVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvkO4dIUUN3ME22MlY5Ozh5IN88US=> NYT3UWhoW0GQR1XS
EB-3 NGT6ZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjmTWM2OD15LkC3NlM{KM7:TR?= NGCzSJZUSU6JRWK=
697 NGnZOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTlwMkSzNlkh|ryP NH25WXpUSU6JRWK=
Ramos-2G6-4C10 MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\5T5BkUUN3ME25MlU6QDR{IN88US=> MUnTRW5ITVJ?
KNS-81-FD NY\UNVJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTlwNkm2OVMh|ryP MXfTRW5ITVJ?
HUTU-80 M2K3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\XWFFDUUN3ME25Mlc1PjR{IN88US=> NITtNoRUSU6JRWK=
LS-411N MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{O1ZmlEPTB;MUCuNFU3PyEQvF2= NGXq[FhUSU6JRWK=
RPMI-8402 MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X3OGlEPTB;MUCuNVE3KM7:TR?= M4KzbXNCVkeHUh?=
KU812 NXuwcHF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLM[JdWUUN3ME2xNE4zQTlzIN88US=> NEHpUWpUSU6JRWK=
EW-1 MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3HTWM2OD1zMD60OFI2KM7:TR?= Mn6yV2FPT0WU
HC-1 NGrZVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1GzUGlEPTB;MUCuOFg1PCEQvF2= NH;xcpdUSU6JRWK=
NB69 NH\tZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfMZZNKSzVyPUGwMlUxPDNizszN M4WwZXNCVkeHUh?=
MFH-ino MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV6yeJE3UUN3ME2xNE45OzB|IN88US=> MWrTRW5ITVJ?
CCRF-CEM NIrnUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XSdGlEPTB;MUGuOVk4KM7:TR?= M372UXNCVkeHUh?=
SK-N-DZ MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTpNGM2UUN3ME2xNk4xPDN4IN88US=> NEHjbVRUSU6JRWK=
NCI-H720 M2S3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3vSmdKSzVyPUGyMlE4ODVizszN MlvKV2FPT0WU
HCC1187 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX0TWM2OD1zMj6yNFQyKM7:TR?= MYPTRW5ITVJ?
IST-SL2 NUKzUG1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInLXYlKSzVyPUGyMlQ5PzJizszN MWjTRW5ITVJ?
KE-37 NGLxbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fNfWlEPTB;MUKuO|k3PiEQvF2= NUn6fWVOW0GQR1XS
HCC1599 NVXIdlBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPYTWM2OD1zMj65NFY6KM7:TR?= MUHTRW5ITVJ?
A4-Fuk NFr6dYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL0fHZKSzVyPUGyMlk2QDZizszN MlfnV2FPT0WU
NKM-1 M1y2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf5TWM2OD1zMz6yPVI2KM7:TR?= M1OxNnNCVkeHUh?=
BE-13 NF3uRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXybJg2UUN3ME2xN{44QTh7IN88US=> NXr4RlhUW0GQR1XS
MV-4-11 M3Twdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:2c3ZKSzVyPUG0MlA{OjRizszN MlfkV2FPT0WU
OPM-2 NH7O[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nMUGlEPTB;MUSuOFA5PSEQvF2= MXXTRW5ITVJ?
KARPAS-422 MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTF2LkWxNlYh|ryP M1jOUnNCVkeHUh?=
RPMI-8226 NUnnNGljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr1fFhnUUN3ME2xOE45QTF3IN88US=> NHz0d4VUSU6JRWK=
KARPAS-45 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\4ZVhKSzVyPUG1Mlc4OTZizszN M17jOnNCVkeHUh?=
SK-PN-DW M4\5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrEc3RKSzVyPUG1Mlg3OzFizszN MWnTRW5ITVJ?
LC-2 MojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfPbnN4UUN3ME2xOk4yPTB4IN88US=> MnzGV2FPT0WU
NCI-H1648 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MliwTWM2OD1zNj6yOVQh|ryP M{TRVXNCVkeHUh?=
RL95-2 NXHrWZZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rxb2lEPTB;MU[uN|k4QCEQvF2= M2f4V3NCVkeHUh?=
KNS-42 M4G4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;EenJJUUN3ME2xOk44Ojd2IN88US=> M3npWnNCVkeHUh?=
RPMI-6666 M4jz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTF4LkmyNVEh|ryP NIXL[2RUSU6JRWK=
SIG-M5 NHPEcZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[xOHhKSzVyPUG3MlE6ODNizszN Mnz1V2FPT0WU
VA-ES-BJ MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTF5Lke0OVEh|ryP Mo\mV2FPT0WU
MONO-MAC-6 NFnjUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnZO3NKSzVyPUG3Mlk{OTJizszN NGr0PFNUSU6JRWK=
LAN-6 M4e2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIO4V|FKSzVyPUG4Mlc2PTdizszN NHzvSGtUSU6JRWK=
A388 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXudZFKSzVyPUG5MlMxPTlizszN MlfWV2FPT0WU
SK-NEP-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT1TWM2OD1{MD6yNVMzKM7:TR?= NY[4OoVtW0GQR1XS
TE-10 NESxZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJyLkWyNlEh|ryP MX;TRW5ITVJ?
HL-60 NX3qeFFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\a[mlKSzVyPUKwMlkxQTlizszN NILnRXlUSU6JRWK=
MC116 MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJzLkeyNlEh|ryP NYmzW3lvW0GQR1XS
SW962 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXjTWM2OD1{MT63PVE2KM7:TR?= MmXVV2FPT0WU
NOMO-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJ{Lk[1OlQh|ryP M4W5enNCVkeHUh?=
CTB-1 NH;Od4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnrXFNsUUN3ME2yNk45PjdzIN88US=> MmrNV2FPT0WU
MRK-nu-1 NXG0cnN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPETWM2OD1{Mj65NFc1KM7:TR?= NInpdIZUSU6JRWK=
GR-ST MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTGTWM2OD1{Mz63OkDPxE1? MlnOV2FPT0WU
HH MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJ2LkCwN{DPxE1? MV\TRW5ITVJ?
NCI-H1963 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfhd3ZKSzVyPUK0MlA4QDJizszN NHnhZWdUSU6JRWK=
QIMR-WIL MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;PTWM2OD1{ND64O|czKM7:TR?= MVXTRW5ITVJ?
CGTH-W-1 NFzue5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJ3LkC3NlMh|ryP MUHTRW5ITVJ?
LP-1 M4O1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJ3Lk[1OVEh|ryP MkTvV2FPT0WU
NCI-H748 MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJ4LkWxN|ch|ryP MVnTRW5ITVJ?
PF-382 MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[zXFFKSzVyPUK3MlIzOjNizszN NXruRXROW0GQR1XS
ATN-1 NXO5RYtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1X5R2lEPTB;MkeuN|c{OiEQvF2= Mnn3V2FPT0WU
L-540 NGDO[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPCPGZ{UUN3ME2yO{43PDV7IN88US=> NWPGS2k2W0GQR1XS
LXF-289 MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ5Lke1NVkh|ryP M2HtfnNCVkeHUh?=
LS-513 NHm3NGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJ6LkG4NFch|ryP NE\FUldUSU6JRWK=
NCI-H1581 NFnuPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTNyLkO5O|Yh|ryP NH3h[FNUSU6JRWK=
ES6 NELUboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnXTWM2OD1|MD62PFk6KM7:TR?= MXfTRW5ITVJ?
SW982 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTNyLki1OlYh|ryP MlHTV2FPT0WU
DOHH-2 MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XpVGlEPTB;M{GuOVg6OyEQvF2= NXHPW5NnW0GQR1XS
DB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zC[GlEPTB;M{OuPVQ{OSEQvF2= NWjKdZNGW0GQR1XS
MPP-89 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfTeHVlUUN3ME2zOE4yPzV4IN88US=> MWnTRW5ITVJ?
LB831-BLC NHHEVJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPJc|hKSzVyPUO0MlUyQDRizszN NG\QPXBUSU6JRWK=
NB5 NIHLOmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3POPGlEPTB;M{SuPFU{PSEQvF2= MWHTRW5ITVJ?
GB-1 NXr1cGl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTN3LkC0Olkh|ryP NWXrV|dYW0GQR1XS
TE-15 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzvb|dqUUN3ME2zOU4zOjN6IN88US=> NXLpSWN{W0GQR1XS
LC4-1 M1q2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXRUmtbUUN3ME2zOU4{QDR5IN88US=> NGTO[lVUSU6JRWK=
NCI-H747 MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTN4LkGzOlkh|ryP NYjTdG5JW0GQR1XS
NTERA-S-cl-D1 NFnJUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG1TWM2OD1|OD63N|Q4KM7:TR?= NHjqco9USU6JRWK=
SK-MM-2 M{PISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnRTWM2OD12MD6xNVQ3KM7:TR?= NGTxXGlUSU6JRWK=
TGW MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXvTWM2OD12MT6wOVY{KM7:TR?= NFjEVGFUSU6JRWK=
ONS-76 MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonRTWM2OD12Mj60PFg{KM7:TR?= NUPkUphTW0GQR1XS
CPC-N NIXVU5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTR{Lkm5O|Eh|ryP M3\tWnNCVkeHUh?=
ES4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTR2LkSxOVMh|ryP MVnTRW5ITVJ?
Daudi NHnVfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrLTWM2OD12NT6wPFI4KM7:TR?= M{LjbXNCVkeHUh?=
MOLT-4 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn4eWk5UUN3ME20OU4xQDV|IN88US=> MmjZV2FPT0WU
HT-144 M1LmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTR4LkeyOkDPxE1? NF3KN4VUSU6JRWK=
SW872 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTR6LkG5N|Mh|ryP NIe5b2NUSU6JRWK=
D-283MED NV7BO2JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTR6LkO1OFIh|ryP MXXTRW5ITVJ?
NCI-H2126 NHPi[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTR6Lki0O|Yh|ryP NYfuVnF{W0GQR1XS
NCI-SNU-16 NULPXmtST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTR7LkKxOFMh|ryP MUDTRW5ITVJ?
CESS MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;OTWM2OD12OT61NFg5KM7:TR?= M4TEPXNCVkeHUh?=
A101D NXniRlBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTR7Lkm3N|Yh|ryP MVPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pALK / pAKT / pERK / pS6; 

PubMed: 24675041     


H3122 cells were treated with the indicated concentrations of crizotinib or ceritinib for 6 hours. Lysates were probed with antibodies directed against the specified proteins.

pROS1 / ROS1; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.

pSTAT3 / STAT3; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.

PARP / cleaved caspase-3 / Bax / Bcl-2; 

PubMed: 25193856     


The expression of PARP, cleaved caspase-3, Bax, and Bcl-2 were measured by western blotting after PANC-1 cells were treated with various concentrations of Crizotinib (0-10 μM) for 72 hr.

p-c-Met / c-Met; 

PubMed: 25193856     


Cancer cells with c-MET alterations were exposed to Crizotinib (10 μM) in the indicated times (SNU-5, MKN-45, and SNU-638: gastric cancer cells of c-MET amplification).

p-mTOR; 

PubMed: 26384345     


Immunoblotting for phospho- or total MET, STAT3, AKT, MTOR and ERK in SPC-A1 cells treated with crizotinib for 48 h.

24675041 25351743 25193856 26384345
Immunofluorescence
LC3 / lysosome; 

PubMed: 26384345     


Cells were treated with DMSO or 4 μM crizotinib for 72 h before they were labeled with a fluorescent marker and imaged by fluorescence microscopy. Green: FITC-labeled LC3; Red: lyso-tracker-labeled lysosome; Blue: DAPI-labeled nucleus. 

SRC / Met; 

PubMed: 26517812     


Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in (A) LN-18 and (B) U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

α-tubulin; 

PubMed: 26517812     


LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

cytochrome c; 

PubMed: 25193856     


PANC-1 pancreatic cancer cells were treated with Crizotinib (1 and 10 μM) for 6 hr and stained with anti-cytochrome c antibody, Mitotracker and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification. Cytochrome c (green), mitotracker: red

p-ALK; 

PubMed: 25193856     


PANC-1 cells were also treated with various concentrations (0-10 μM) of Crizotinib and stained with p-ALK antibody and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification.

26384345 26517812 25193856
体内研究

PF-2341066每天按50 mg/kg和75 mg/kg剂量处理GTL-16 模型, 引起大肿瘤 (体积大于600 mm3) 明显衰退,且按43天处理日程处理后,平均肿瘤体积降低60%。在另一项研究中, PF-2341066处理3个月以上,完全抑制GTL-16肿瘤生长,PF-2341066每天按50 mg/kg剂量处理小鼠,3个月后,只有1/12小鼠的肿瘤生长得到提高。PF-2341066每天按50 mg/kg剂量处理NCI-H441 NSCLC 模型处理周期为38天,观察到平均肿瘤体积降低43%。PF-2341066 每天按50 mg/kg剂量作用于 Caki-1 RCC模型,处理周期为33天,观察到平均肿瘤体积降低53%,且每种肿瘤体积降低至少30%。PF-2341066每天按 50 mg/kg剂量作用于 U87MG 恶性胶质瘤或PC-3前列腺癌移植瘤模型,几乎完全抑制肿瘤生长,在实验最后一天,抑制分别达97% 或84%。相反, PF-2341066每天按50 mg/kg剂量口服给药处理 MDA-MB-231 乳腺癌模型,或 DLD-1 结肠癌模型,不会显著抑制肿瘤生长。PF-2341066每天按12.5 mg/kg, 25 mg/kg, 和50 mg/kg剂量作用于 GTL-16 肿瘤,观察到CD31阳性内皮细胞显著降低,这种作用存在剂量依赖性,说明 MVD 受抑制,且具有相关的抗癌高效性,这种作用也存在剂量依赖性。PF-2341066 作用于GTL-16 和 U87MG 模型,显著降低人VEGFA 和IL-8血浆水平,这种作用存在剂量依赖性。PF-2341066口服处理GTL-16 肿瘤,观察到磷酸化的c-Met, Akt, Erk, PLCλ1,和 STAT5水平显著受抑制。[1]PF-2341066 每天按100 mg/kg剂量口服处理携带Karpas299 ALCL 移植瘤的SCID Beige 小鼠,具有抗癌高效性,这种作用存在剂量依赖性,处理15天,所有肿瘤完全衰退。此外, PF-2341066抑制关键NPM-ALK信号调节器, 包括磷脂酶C-γ, 信号转导器,及转录因子3, 细胞外信号调节激酶, 和Akt的激活剂,这些与 NPM-ALK 磷酸化和功能受抑制相关。[2] PF-2341066 抑制骨肉瘤的一些活动行为,及其肿瘤生长(例如, 增殖和存活)和转移 (例如,入侵和形成克隆)。PF-2341066口服饲喂裸鼠,抑制生长和相关的骨肉瘤裸鼠移植瘤的骨基质的形成。[3] PF-2341066 按50 mg/kg 剂量处理 c-MET-扩增的GTL-16移植瘤,引起肿瘤衰退,这与18F-FDG 摄取的缓慢降低相关,且降低葡糖糖转运蛋白 1, GLUT-1的表达。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

生化激酶实验:

使用连续耦合的分光光度测定c-Met催化活性,通过分析NADH消耗率而测定c-Met诱导的ADP产量,这种作用具有时间依赖性。在 340 nm处使用分光光度法在指定时间点测定吸光值的降低而计算NADH的消耗量。为了测定Ki值, 在含实验试剂的实验孔中加入不同浓度PF-2341066,然后在37oC下温育10分钟。加入c-Met酶开始进行实验反应。
细胞实验:

[1]

- 合并
  • Cell lines: GTL-16胃癌细胞和T47D乳腺癌细胞
  • Concentrations: 0 nM-256 nM
  • Incubation Time: 1小时
  • Method:

    GTL-16胃癌细胞和T47D乳腺癌细胞接种在96孔板上,孔中含培养基,培养基中含10% 胎牛血清(FBS),然后转移到无血清培养基中[含0.04%牛血清蛋白(BSA)],处理 24小时。 在调查配体依赖的RTK 磷酸化实验中,加入相应的生长因子,处理20分钟。细胞和 PF-2341066和/或适当配体在指定时间温育1小时,然后使用含 1 mmol/L Na3VO4的HBSS冲洗细胞一次,然后从细胞中获得蛋白裂解物。随后,通过夹心酶联免疫吸附试验法使用特定的捕获抗体在96孔板上测定选定蛋白激酶的磷酸化,使用特点检测抗体测定磷酸化的酪氨酸残基。抗体包被的实验板(a) 在蛋白裂解物存在时,在4oC下过夜;(b)在溶于PBS的1% Tween-20 中冲洗7次;(c)在辣根过氧化物酶标记的抗总磷酸(PY-20)抗体(1:500)中温育20分钟;(d) 再次冲洗7次;(e)在3,3,5,5-四甲基联苯胺过氧化物酶底物中温育,开始显示反应,加入0.09 N H2SO4终止反应; (f)在450 nm 处使用分光光度计测定吸光度。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 携带NCI-H441,或DLD-1,或MDA-MB-231的雌性和雄性nu/nu小鼠
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 和50 mg/kg/day
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+dd H2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 450.34
化学式

C21H22Cl2FN5O

CAS号 877399-52-5
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04148066 Recruiting Diagnostic Test: ctDNA blood sample Carcinoma Non-Small-Cell Lung The Netherlands Cancer Institute|Roche Pharma AG July 17 2019 Phase 2
NCT03439215 Recruiting Drug: Lorlatinib Carcinoma Non-Small-Cell Lung Fondazione Ricerca Traslazionale|Clinical Research Technology S.r.l. June 13 2017 Phase 2
NCT02946216 Unknown status Genetic: ctDNA analysis Non-small Cell Lung Cancer Stage III|Non-Small-Cell Lung Cancer Metastatic|Adenocarcinoma of Lung|EGFR Wildtype First People''s Hospital of Hangzhou November 2016 --
NCT02511184 Terminated Drug: Crizotinib|Drug: Pembrolizumab ALK-positive Advanced NSCLC Pfizer|Merck Sharp & Dohme Corp. October 2015 Phase 1
NCT02419287 Unknown status Drug: crizotinib Anaplastic Large Cell Lymphoma ALK-Positive University of Milano Bicocca April 2015 Phase 2
NCT02499614 Unknown status Drug: Crizotinib Carcinoma Non-Small-Cell Lung Fondazione Ricerca Traslazionale December 2014 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • 回答:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

相关c-Met产品

Tags: 购买Crizotinib (PF-02341066) | Crizotinib (PF-02341066)供应商 | 采购Crizotinib (PF-02341066) | Crizotinib (PF-02341066)价格 | Crizotinib (PF-02341066)生产 | 订购Crizotinib (PF-02341066) | Crizotinib (PF-02341066)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID